Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
J Thorac Oncol. 2010 Feb;5(2):236-9. doi: 10.1097/JTO.0b013e3181c3f5f7.
A prospective study was conducted at the lung cancer clinic of a tertiary care institute to assess the incidence of and reasons for intercycle delays (ICD) during chemotherapy of patients with non-small cell lung cancer (NSCLC). The effect of ICD on overall survival was also assessed.
Data were collected for all newly diagnosed NSCLC patients who were initiated on and completed chemotherapy during a 12-month period. Differences between patients who experienced ICD (ICD+ group) versus those who did not (ICD- group) were analyzed. Survival probabilities and median survivals were calculated by Kaplan-Meier method, and group differences were analyzed using the log-rank test.
Of the 118 chemonaive NSCLC patients who received chemotherapy, 100 received > or =2 cycles and were included in data analysis. A total of 441 cycles were administered with ICD amounting to 683 days being noted during 84 (19.1%) cycles in 57 patients. The most common reasons for ICD were nonavailability of blood tests reports (25.5%), severe anemia (20.2%), and hospital holidays on scheduled days of chemotherapy (9.6%). ICD+ and ICD- groups did not differ with respect to age, gender, smoking status, histology, stage of disease, baseline performance status, chemotherapy regimen, or number of cycles administered. Median survival in ICD+ and ICD- groups was similar (247 [95% confidence interval 188-306 days] and 232 days [95% confidence interval 196-268 days], respectively).
ICD are common during chemotherapy of NSCLC patients in our institute. Factors unrelated to disease status or chemotherapy regimen are important reasons. ICD did not affect overall survival in the current study.
本研究为前瞻性研究，在一家三级医院的肺癌临床科室进行，旨在评估非小细胞肺癌（NSCLC）患者化疗过程中周期间延迟（ICD）的发生率和原因。同时评估 ICD 对总生存期的影响。
对 12 个月期间新诊断为 NSCLC 且开始并完成化疗的所有患者进行数据收集。分析经历 ICD（ICD+组）与未经历 ICD（ICD-组）的患者之间的差异。采用 Kaplan-Meier 法计算生存概率和中位生存时间，采用对数秩检验分析组间差异。
在接受化疗的 118 例化疗初治 NSCLC 患者中，100 例接受了≥2 个周期的化疗，纳入数据分析。共给予 441 个周期的化疗，84 个周期（57 例患者）出现 ICD，共计 683 天。ICD 的最常见原因是血液检查报告缺失（25.5%）、严重贫血（20.2%）和化疗日恰逢医院假期（9.6%）。ICD+和 ICD-组在年龄、性别、吸烟状况、组织学、疾病分期、基线体能状态、化疗方案或给予的周期数方面无差异。ICD+和 ICD-组的中位生存时间相似（分别为 247[95%置信区间 188-306 天]和 232 天[95%置信区间 196-268 天]）。
在本研究中，我院 NSCLC 患者化疗期间 ICD 较为常见。与疾病状态或化疗方案无关的因素是重要的原因。在当前研究中，ICD 并未影响总生存期。
